Immune profiling to detect viral hepatitis-related liver cancer in HIV-infected patients
免疫分析检测 HIV 感染者中病毒性肝炎相关肝癌
基本信息
- 批准号:10536532
- 负责人:
- 金额:$ 22.65万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-07-01 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:AFP geneAddressAdherenceAfricaAgeApoptosisBiologicalBiological MarkersBloodBlood TestsBlood VesselsBrazilCD4 Lymphocyte CountCancer EtiologyCessation of lifeChronicCirrhosisCollaborationsDataDetectionDevelopmentDiagnosticEarly DiagnosisEnrollmentEnvironmentEuropeFutureGastroenterologyGenderGoalsGuidelinesHIVHIV InfectionsHIV SeronegativityHIV SeropositivityHIV/HCVHepaticHepatitisHepatitis BHepatitis B InfectionHepatitis CHepatitis C virusHepatocarcinogenesisIL3 GeneImmuneImmunologic MarkersIndividualInfectionInternationalLatin AmericaLeadLiverLiver CirrhosisMalignant NeoplasmsMalignant neoplasm of liverMeasurableMeasuresNodulePatientsPerformancePeripheralPersonsPhasePopulationPrimary carcinoma of the liver cellsProcessProspective cohortProteinsReportingResearchRiskRisk FactorsSamplingSecond Primary NeoplasmsSecondary toSensitivity and SpecificitySeriesSerumSiteSouth AmericanStandardizationTNFSF10 geneTestingTimeTrainingTransplantationUltrasonographyUnited StatesValidationVariantVascular Endothelial Growth FactorsViral hepatitisVirusVirus DiseasesVisualchronic liver diseaseco-infectioncohortcytokinedifferential expressionearly detection biomarkershepatocyte injuryhigh riskimmunogenicimmunoreactioninnovationinterleukin-22liver transplantationnovelprospectivepublic health relevancescreeningtumorultrasound
项目摘要
Hepatocellular carcinoma (HCC) is the most frequent malignancy of the liver and the second most common
cause of cancer-related death worldwide. HCC occurs in the setting of chronic liver disease, and infections with
hepatitis B (HBV) and hepatitis C virus (HCV), are the most common underlying HCC risk factor worldwide.
The risk of HCC is heightened in those infected with HIV. Indeed, HIV-positive individuals are frequently co-
infected with HBV or HCV, priming them for liver-related complications. Moreover, studies have consistently
shown that HIV-positive individuals living with HBV or HCV develop HCC at younger ages than their HIV-
negative counterparts. Currently, individuals with HIV and co-infection with viral hepatitis at risk for HCC are
advised to undergo ultrasonography of the liver every 6 months with the goal of “visually” identifying a tumor.
This visual screening approach has poor adherence and is dependent on the ultrasound operator expertise.
We hypothesize that a non-visual screening approach with standardized immune-related blood biomarkers
may be a sensible alternative approach. Our group recently identified a series of immune markers detected in
serum of patients with hepatitis that were able to predict the future development of HCC, even when the cancer
occurred two years later.
In this project, we will investigate whether a hyper-immune environment, product of the continuous presence of
the virus in body, could lead to measurable immune analytes in serum so as to predict early HCC. Using our
multinational on-going collaborations of the SALRN and ESCALON networks in Latin America, we propose to
cross-sectionally and prospectively evaluate peripheral immune variations in HIV-infected individuals as
markers to predict early HCC development.
In Specific Aim 1, we will determine if novel immune signatures in the serum of persons co-infected with
viral hepatitis B or C and HIV are differentially expressed in those with hepatocellular carcinoma
(discovery phase). We will analyze serum samples collected via SALRN and ESCALON studies as a training set
to evaluate if a pre-defined panel of immune analytes measured via multiplex cytokine analysis is differentially
expressed in HIV-infected HCC cases compared to age-gender matched HIV controls without HCC.
In Specific Aim 2, we will determine if immune signatures can accurately differentiate HIV-infected
individuals co-infected with hepatitis B or C with hepatocellular carcinoma from those without tumor
(validation phase). We will collect samples from HIV-infected subjects in a single HIV high-endemicity site in
Brazil via the existing ESCALON study network as a validation set to determine the ability of the signature to
detect HCC.
This study will generate innovative data related to biomarkers for early detection of HCC in HIV-infected
individuals and provide the basis for a larger prospective cohort for HCC biomarkers in HIV.
肝细胞癌 (HCC) 是最常见的肝脏恶性肿瘤,也是第二常见的肝脏恶性肿瘤
全球癌症相关死亡的原因。 HCC 发生在慢性肝病和感染的情况下
乙型肝炎 (HBV) 和丙型肝炎病毒 (HCV) 是全球最常见的潜在 HCC 危险因素。
感染艾滋病毒的人患肝癌的风险会增加。事实上,艾滋病毒阳性者经常与
感染 HBV 或 HCV,从而引发肝脏相关并发症。此外,研究不断
研究表明,感染 HBV 或 HCV 的 HIV 阳性个体比 HIV 感染者更年轻地患上 HCC。
负面对应。目前,HIV 感染者和病毒性肝炎合并感染者有患 HCC 的风险
建议每 6 个月进行一次肝脏超声检查,目的是“目视”识别肿瘤。
这种视觉筛查方法的依从性较差,并且依赖于超声操作员的专业知识。
我们假设采用标准化免疫相关血液生物标志物的非视觉筛查方法
可能是一种明智的替代方法。我们的小组最近发现了一系列免疫标记物
肝炎患者的血清能够预测 HCC 的未来发展,即使癌症已经发生
发生在两年后。
在这个项目中,我们将调查超免疫环境是否是持续存在的产物
体内的病毒可能会导致血清中产生可测量的免疫分析物,从而预测早期肝癌。使用我们的
拉丁美洲的 SALRN 和 ESCALON 网络正在进行的跨国合作,我们建议
横断面和前瞻性地评估 HIV 感染者的外周免疫变异
预测早期 HCC 发展的标志物。
在具体目标 1 中,我们将确定同时感染者的血清中是否存在新的免疫特征
乙型或丙型病毒性肝炎和 HIV 在肝细胞癌患者中存在差异表达
(发现阶段)。我们将分析通过 SALRN 和 ESCALON 研究收集的血清样本作为训练集
评估通过多重细胞因子分析测量的预定义免疫分析物组是否存在差异
与年龄性别匹配的无 HCC 的 HIV 对照相比,在 HIV 感染的 HCC 病例中表达。
在具体目标 2 中,我们将确定免疫特征是否可以准确区分 HIV 感染者
合并感染乙型或丙型肝炎且无肿瘤的肝细胞癌的个体
(验证阶段)。我们将从一个艾滋病毒高流行地点的艾滋病毒感染者身上收集样本
巴西通过现有的 ESCALON 研究网络作为验证集来确定签名的能力
检测肝癌。
这项研究将生成与生物标志物相关的创新数据,用于早期检测 HIV 感染者的 HCC
个体,并为 HIV 中 HCC 生物标志物的更大前瞻性队列提供基础。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jose Daniel Debes其他文献
Jose Daniel Debes的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jose Daniel Debes', 18)}}的其他基金
Immune profiling to detect viral hepatitis-related liver cancer in HIV-infected patients
免疫分析检测 HIV 感染者中病毒性肝炎相关肝癌
- 批准号:
10703227 - 财政年份:2022
- 资助金额:
$ 22.65万 - 项目类别:
Impact of Hepatitis C and HIV coinfection on biological aging and hepatocellular carcinoma risk
丙型肝炎和艾滋病毒合并感染对生物衰老和肝细胞癌风险的影响
- 批准号:
10872804 - 财政年份:2022
- 资助金额:
$ 22.65万 - 项目类别:
Regulation of host cell gene expression by the hepatitis C virus protein NS5A
丙型肝炎病毒蛋白 NS5A 对宿主细胞基因表达的调节
- 批准号:
8251563 - 财政年份:2012
- 资助金额:
$ 22.65万 - 项目类别:
Regulation of host cell gene expression by the hepatitis C virus protein NS5A
丙型肝炎病毒蛋白 NS5A 对宿主细胞基因表达的调节
- 批准号:
8400739 - 财政年份:2012
- 资助金额:
$ 22.65万 - 项目类别:
相似海外基金
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
- 批准号:
10594350 - 财政年份:2023
- 资助金额:
$ 22.65万 - 项目类别:
Evaluating Centralizing Interventions to Address Low Adherence to Lung Cancer Screening Follow-up in Decentralized Settings
评估集中干预措施,以解决分散环境中肺癌筛查随访依从性低的问题
- 批准号:
10738120 - 财政年份:2023
- 资助金额:
$ 22.65万 - 项目类别:
Suubi-Mhealth: A mobile health intervention to address depression and improve ART adherence among Youth living with HIV (YLHIV) in Uganda
Suubi-Mhealth:一种移动健康干预措施,旨在解决乌干达艾滋病毒感染者 (YLHIV) 青少年的抑郁症问题并提高抗逆转录病毒疗法的依从性
- 批准号:
10526768 - 财政年份:2022
- 资助金额:
$ 22.65万 - 项目类别:
Suubi-Mhealth: A mobile health intervention to address depression and improve ART adherence among Youth living with HIV (YLHIV) in Uganda
Suubi-Mhealth:一种移动健康干预措施,旨在解决乌干达艾滋病毒感染者 (YLHIV) 青少年的抑郁症问题并提高抗逆转录病毒疗法的依从性
- 批准号:
10701072 - 财政年份:2022
- 资助金额:
$ 22.65万 - 项目类别:
A behavioral intervention for Black men who have sex with men and live with HIV to address intersectional stigma and improve antiretroviral therapy adherence
针对男男性行为且感染艾滋病毒的黑人男性进行行为干预,以解决交叉耻辱并提高抗逆转录病毒治疗的依从性
- 批准号:
10679092 - 财政年份:2021
- 资助金额:
$ 22.65万 - 项目类别:
A behavioral intervention for Black men who have sex with men and live with HIV to address intersectional stigma and improve antiretroviral therapy adherence
针对男男性行为且感染艾滋病毒的黑人男性进行行为干预,以解决交叉耻辱并提高抗逆转录病毒治疗的依从性
- 批准号:
10432133 - 财政年份:2021
- 资助金额:
$ 22.65万 - 项目类别:
A behavioral intervention for Black men who have sex with men and live with HIV to address intersectional stigma and improve antiretroviral therapy adherence
针对男男性行为且感染艾滋病毒的黑人男性进行行为干预,以解决交叉耻辱并提高抗逆转录病毒治疗的依从性
- 批准号:
10327065 - 财政年份:2021
- 资助金额:
$ 22.65万 - 项目类别:
Leveraging Technology to Address Access and Adherence to Conventional Hospital-Based Pulmonary Rehabilitation in Veterans with COPD
利用技术解决慢性阻塞性肺病退伍军人接受和坚持传统医院肺康复的问题
- 批准号:
10377366 - 财政年份:2019
- 资助金额:
$ 22.65万 - 项目类别:
Leveraging Technology to Address Access and Adherence to Conventional Hospital-Based Pulmonary Rehabilitation in Veterans with COPD
利用技术解决慢性阻塞性肺病退伍军人接受和坚持传统医院肺康复的问题
- 批准号:
10574496 - 财政年份:2019
- 资助金额:
$ 22.65万 - 项目类别:
Targeted interventions to address the multi-level effects of gender-based violence on PrEP uptake and adherence among adolescent girls and young women in Kenya
有针对性的干预措施,以解决性别暴力对肯尼亚少女和年轻妇女接受和坚持 PrEP 的多层面影响
- 批准号:
9403567 - 财政年份:2017
- 资助金额:
$ 22.65万 - 项目类别:














{{item.name}}会员




